World Journal of Surgical Oncology · 2018 · 58 citations · 30 references
MedicineMolecular BiologyOncologyApoptosisImmunoregulationMolecular OncologyCancer BiomarkersCancer ImmunotherapyCervical CancerImmuno-oncology BiomarkersMalignant NeoplasmsTumor Suppressor GenesCell Viability AssaysDual-luciferase AssaysLuciferase Reporter AssaysLuciferase ReportersWestern Blot AnalysisWestern Blotting
BACKGROUND: As indoleamine-2,3-dioxygenase 1 (IDO1) is critical in tumor immune escape, we determined to study the regulatory mechanism of miR-218 on IDO1 in cervical cancer. METHODS: Real-time PCR (RT-qPCR) was carried out to measure the expression of miR-218. RT-qPCR and Western blot were performed to detect the expression of IDO1 in cervical cancer. Dual-luciferase reporter assay was used to determine the binding of miR-218 on the IDO1 3'UTR. Cell viability, apoptosis, and related factors were determined using cell counting kit-8 (CCK-8), Annexin-V/PI (propidium) assay, enzyme-linked immunosorbnent assay (ELISA), RT-qPCR, and Western blot assays after miR-218 mimics has been transfected to HeLa cervical cancer cells. RESULTS: MiR-218 was downregulated in cervical cancer. The expression of miR-218 was negatively correlated with IDO1 in cervical cancer tissues and cells. IDO1 is a direct target of miR-218. MiR-218 overexpression was found to inhibit cell viability and promoted apoptosis via activating the expression of Cleaved-Caspase-3 and to inhibit the expression of Survivin, immune factors (TGF-β, VEGF, IL-6, PGE2, COX-2), and JAK2/STAT3 pathway. CONCLUSION: MiR-218 inhibits immune escape of cervical cancer cells by direct downregulating IDO1.
30
Jan Paul Medema, Joan de Jong, Lucy T.C. Peltenburg et al. · Proceedings of the National Academy of Sciences · 2001 · 350 citations · Full text
Life Sciences, Immunology, Oncology +17
Steven C. Fausch, Michael P. Rudolf, W. Martin Kast · The Journal of Immunology · 2002 · 142 citations · Full text
Martina Niebler, Xu Qian, Daniela Höfler et al. · PLoS Pathogens · 2013 · 130 citations · Full text
Life Sciences, Immunology, Oncology +17